Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Ionis Pharmaceuticals, Inc.”

202 pharma patents match "Ionis Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 202
Index total 30,257
Page 2 / 9

Quick answer

This filtered view shows 202 pharmaceutical patents matching "Ionis Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

202 results for “Ionis Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 11873495

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 16, 2024 · Expires Jan 11, 2044

    granted
  2. US 11859180

    Antisense oligonucleotide compositions

    Ionis Pharmaceuticals, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  3. US 11851655

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  4. US 11840686

    Modulation of prekallikrein (PKK) expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  5. US 11840689

    Method of treating fatty liver disease

    Ionis Pharmaceuticals, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  6. US 11833221

    Oligomeric compounds for reducing DMPK expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  7. US 11834660

    Compositions for modulating Ataxin 2 expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  8. US 11833168

    Compounds and methods for increasing STMN2 expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  9. US 11786546

    Compounds and methods for modulating GFAP

    Ionis Pharmaceuticals, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  10. US 11781143

    Modulators of PNPLA3 expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  11. US 11761000

    Compositions and their uses directed to huntingtin

    Ionis Pharmaceuticals, Inc. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  12. US 11753644

    Compounds and methods for reducing IFNAR1 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  13. US 11732265

    Compositions and methods for modulating complement factor B expression

    Ionis Pharmaceuticals, Inc. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  14. US 11725208

    Conjugated antisense compounds and their use

    Ionis Pharmaceuticals, Inc. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted
  15. US 11713462

    Modulation of GYS1 expression

    Ionis Pharmaceuticals, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  16. US 11634711

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  17. US 11633483

    Modulators of PCSK9 expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  18. US 11629348

    Linkage modified oligomeric compounds and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  19. US 11613752

    Compositions and methods for modulating PKK expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted
  20. US 11583548

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  21. US 11547718

    Modulators of FOXP3 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  22. US 11542504

    Compounds and methods for modulating ATXN1

    Ionis Pharmaceuticals, Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  23. US 11535849

    Modulation of transthyretin expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  24. US 11530411

    Methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted